Table 1: Psoriasis patients at baseline.
Characteristics of psoriasis patients at baseline.
| Variable | Baseline (N=122) |
|---|---|
| Demographic and clinical characteristics | |
| Age, years | 49.6 ± 13.0 |
| Males | 71 (58) |
| Caucasian | 98 (80) |
| Hypertension | 35 (29) |
| Hyperlipidemia | 60 (49) |
| Type-2 diabetes | 13(11) |
| Body Mass Index | 30.0 ± 6.4 |
| Waist-to-hip ratio | 0.95 (0.89–1.00) |
| Current smoker | 11 (9) |
| Statin use | 39 (32) |
| Clinical and lab values | |
| Total cholesterol, mg/dl | 183.8 ± 35.0 |
| HDL cholesterol, mg/dl | 55.3 ± 17.2 |
| LDL cholesterol, mg/dl | 104.2 ± 29.6 |
| Triglycerides, mg/dl | 125.2 ± 83.9 |
| Framingham Risk Score | 3 (1–6) |
| High-sensitivity C-reactive protein, mg/L | 2.1 (0.87–4.5) |
| Psoriasis characterization | |
| Psoriasis Area Severity Index Score | 5.5 (3.2–10.7) |
| Systemic or biologic treatment | 32 (27) |
| Vitamin D parameters | |
| 1,25 (OH) 2D (ng/ml) | 52.4 ± 15.2 |
| 25 (OH) D (ng/ml) | 28.7 ± 14.0 |
| Vascular characterization | |
| Aortic target-to-background ratio (TBR) | 1.74 ± 0.27 |
| Non-calcified coronary burden, mm2 (×100) | 1.13 ± 0.59 |
| Adiposity | |
| Visceral adiposity (cm3) | 16346±9489 |
| Subcutaneous adiposity (cm3) | 21375±12239 |
Values reported in the table as mean ± SD or median (IQR) for continuous data and N (%) for categorical data.